Objective: To determine whether the Parkinson disease-related covariance pattern (PDRP) expression is abnormally increased in idiopathic REM sleep behavior disorder (RBD) and whether increased baseline activity is associated with greater individual risk of subsequent phenoconversion.
network activity and clinical manifestations in individuals with this disorder. 5, 6 Nonetheless, network activity was found to be elevated in the "presymptomatic" hemisphere (i.e., ipsilateral to the symptomatic body side) in patients with early-stage PD with unilateral motor involvement ("hemi-PD"), anteceding the onset of contralateral limb manifestations by several years. 11 In this study, we used functional imaging to determine whether analogous prodromal network abnormalities were present in individuals with idiopathic RBD and whether abnormal network expression was a predictor of subsequent phenoconversion.
METHODS Subjects. We studied 2 discrete groups of subjects with RBD who were diagnosed according to established criteria. 12 Exclusion criteria were signs or symptoms of other neurologic diseases and RBD secondary to other diseases or medication. Cohort 1 comprised 10 subjects with RBD recruited at the sleep disorders clinics of the North Shore-Long Island Jewish Health System (Manhasset, NY) and the Hospital of the University of Pennsylvania (Philadelphia) between November 2010 and May 2013. These individuals and 10 healthy age-matched volunteer subjects (62.7 6 8.6 years old) underwent metabolic brain imaging with 18 F-fluorodeoxyglucose (FDG)-PET to evaluate resting metabolic activity at both the network and region (nodal) levels. Cohort 2 comprised a second group of subjects with RBD who were recruited at the Sleep Disorders Clinic of the Hôpital du Sacré-Coeur de Montréal (Canada) between February 2003 and July 2008. These subjects and 17 healthy age-matched volunteers (66.6 6 6.0 years old) underwent cerebral perfusion imaging with 99mTc ethylcysteinate dimer (ECD) and SPECT. Limited clinical and imaging data from these subjects have been presented previously. 13, 14 In this study, we used the scan data from cohort 2 to validate the functional brain changes discerned in the first cohort.
Scan data from cohort 2 were additionally used to determine whether the presence of baseline functional abnormalities in individuals with idiopathic RBD was associated with subsequent phenoconversion, as determined by the later development of a defined neurodegenerative syndrome. After baseline imaging, subjects with RBD in this cohort were followed annually by a movement disorders neurologist (R.B.P.) and a neuropsychologist (J.-F.G.). Eight members of this cohort subsequently developed parkinsonism, and were diagnosed with either PD (n 5 5) or DLB (n 5 3) according to established criteria. 15, 16 The remaining 9 subjects with RBD in this group did not phenoconvert during the follow-up period.
Apart from the 17 subjects with RBD in cohort 2, we analyzed baseline ECD SPECT data from 3 additional subjects with idiopathic RBD who subsequently developed signs of atypical parkinsonism. These subjects were diagnosed with probable (n 5 1) or possible (n 5 2) MSA according to consensus criteria. 17 Given that the histopathology of MSA is different from PD/ DLB, and that this neurodegenerative phenotype develops less frequently in idiopathic RBD, 12 these subjects were analyzed as a discrete diagnostic category (see below).
Imaging procedures. Cohort 1 subjects underwent metabolic imaging with FDG-PET in an eyes-open resting state as detailed elsewhere. 8 Subjects recruited at North Shore-Long Island Jewish Health System (n 5 5) were scanned on a GE Advance tomograph (General Electric, Milwaukee, WI). Subjects recruited at the University of Pennsylvania (n 5 5) were scanned on a Biograph 40 mCT-S PET/CT device (Siemens Medical Solutions, Knoxville, TN). Cohort 2 subjects underwent perfusion imaging with ECD SPECT in a similar awake state as previously described. 13 These subjects were scanned using the 3-headed SPECT camera (PRISM system; Picker Co., Cleveland, OH) at Hôpital du Sacré-Coeur de Montréal in Montreal, Canada. Measurements of whole-brain PDRP expression were standardized by z scoring with respect to corresponding values from healthy subjects scanned under the same tomographic conditions. This permitted the comparison of network changes across imaging modalities. 9, 18 In cohort 1, the PDRP scores were standardized based on values computed in FDG-PET scans from the corresponding healthy reference group as described elsewhere. 9, 18 We also computed network activity in cohort 1 subjects on a hemisphere-byhemisphere basis. 11 For each subject, right and left hemisphere PDRP values were z scored with respect to corresponding hemispheric measurements from the healthy control group. For RBD and healthy control subjects, right and left hemisphere PDRP measurements were averaged and compared with analogous values computed in the preclinical (ipsilateral) hemispheres of subjects with early-stage PD and unilateral symptoms. This previously reported cohort comprised 15 subjects with hemi-PD who were scanned with FDG-PET at baseline and again, 2 and 4 years later.
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In cohort 2, we used the same procedure to compute wholebrain PDRP values in the ECD SPECT data. 19, 20 PDRP values computed in this sample were standardized with respect to corresponding measurements from the healthy control subjects for this cohort. As in cohort 1, these automated computations were performed on an individual case basis, blinded to group membership and final clinical status.
In both cohorts, a regional analysis was conducted to assess group differences in resting brain function at the major nodes of the PDRP network. Volumes of interest (VOIs) 8 were defined by 4-mm spheres centered at nodal maxima (table 1) situated in the pons, cerebellum, putamen/globus pallidus, and thalamus and in sensorimotor, lateral premotor, and parietal association cortex. A single midline VOI was placed in the pons and cerebellar vermis; separate right and left VOIs were delineated for the other regions, which were averaged for further analysis. In each VOI, local activity was ratio normalized by the global value for the corresponding scan. Group differences in PDRP expression and in local activity at each node were assessed using 2-tailed Student t tests.
Logistical regression analysis. Logistical regression analysis
was used to determine whether baseline measurements of PDRP expression correlated with the likelihood of subsequent phenoconversion in the RBD follow-up cohort (cohort 2). In these subjects, the individual network values were sealed before the final clinical status of the participants was released. We first tested a 2-category predictive model in which phenoconverters to PD/DLB (n 5 8) were defined as one classification group, while the nonphenoconverters (n 5 9) were defined as the other group. We also tested a 3-category model that included the 3 phenoconverters to possible or probable MSA as a separate classification group. Model selection was based on relative goodness of fit as determined by the Akaike Information Criterion. 21 Categorization accuracy was assessed using likelihood-ratio tests. Group differences in PDRP expression and in regional activity at the major network nodes were evaluated using SPSS software (SPSS Inc., Chicago, IL). In each region, local activity was globally normalized and presented as the mean Logistical regression analysis was performed using SAS 9.1 software (SAS Institute Inc., Cary, NC). Results were considered significant for p , 0.05.
Standard protocol approvals, registrations, and patient consents. Ethical permission for the procedures was obtained from the Institutional Review Board of North Shore University Hospital, Hospital of the University of Pennsylvania, and Hô-pital du Sacré-Coeur de Montréal. Written consent was obtained from each participant after a detailed explanation of the procedures.
RESULTS Clinical follow-up. Demographic and clinical data from cohort 1 and cohort 2 subjects with RBD are summarized in table e-1 on the Neurology ® Web site at www.neurology.org. For the 8 subjects with RBD in cohort 2 who subsequently were diagnosed with PD/DLB, the mean interval between imaging and time of diagnosis was 3.4 6 2.1 years (range, 0.4-6.2 years). The mean interval between imaging and final clinical assessment in the nonphenoconverters was 5. 6 6 2.4 years (range, 3.9-11.3 years) and 4.6 6 2. 5 years (range, 0.4-11.3 years) for the whole cohort. Three additional subjects with RBD (50, 61, and 66 years old; Unified Parkinson's Disease Rating Scale motor ratings 0, 2.5, and 2) were diagnosed with possible or probable MSA and developed signs of atypical parkinsonism 4.3, 2.5, and 2.7 years after imaging. (In cohort 1, the In cohort 2, baseline network activity was higher in the subjects with RBD who subsequently phenoconverted to PD or DLB (n 5 8) relative to those who did not phenoconvert (n 5 9) during the followup period (p , 0.03). In both cohorts, the subjects with RBD displayed increases in PDRP expression that were similar to values measured in the preclinical hemispheres of patients with early-stage PD with unilateral motor signs ( figure 2A, right) . Given the concordance of the PDRP changes observed in RBD cohort 1 and cohort 2, the network abnormality was robust (0.96 6 0.16, p , 0.001) when data from the 2 samples were merged. Group comparison of resting activity at the major PDRP nodes (table 1) revealed consistent regional changes in both RBD groups. Relative to healthy individuals, subjects with RBD exhibited consistent increases in nodal activity (figure 3, A-D) in the pons (cohort 1: p 5 0.021; cohort 2: p 5 0.002) and in the putamen/ globus pallidus (cohort 1: p 5 0.016; cohort 2: p 5 0.047; Student t tests). Of note, local pontine activity (figure 3B, right) was greater in the subjects with RBD who later phenoconverted to PD/DLB relative to their nonphenoconverter counterparts (p , 0.001). Marginal elevations in nodal activity were observed in the thalamus (cohort 1: p 5 0.041; cohort 2: p 5 0.061) and the cerebellum (cohort 1: p 5 0.058; cohort 2: p 5 0.022). The latter node also exhibited a trend-level increase in the phenoconverters relative to the nonphenoconverters (p 5 0.061). Differences in functional activity in the RBD and healthy control groups and between phenoconverters and nonphenoconverters were not significant in the other network regions (p . 0.24).
Network activity: A predictor of later phenoconversion.
Using logistic regression, we first constructed a 2-category predictive model based on PDRP expression in which each subject was classified as either likely to phenoconvert to PD or DLB or as unlikely to phenoconvert. This model exhibited a good fit to the data, accounting for 27.6% of the variance in final clinical status (p , 0.02). Review of the individual data revealed high baseline network activity (subject scores $0.90) in each of the 8 subjects with RBD who subsequently phenoconverted to PD or DLB. Network elevations of similar magnitude were, however, also seen in 3 of the 9 subjects who did not phenoconvert during the followup period ( figure 4A, arrows) . A second predictive model based on subject age at the time of imaging had comparable goodness of fit, accounting for 23.7% of the variance in outcome (p , 0.04). Notably, the correlation between these 2 variables was not significant (p 5 0.58), suggesting their independence as predictors of phenoconversion in RBD. Indeed, goodness of fit improved substantially when both PDRP expression and subject age were entered together into a 2-category predictive model, accounting for 64.0% of the individual differences in phenoconversion status (p , 0.001). Graphical display of the data according to this model ( figure 4B ) revealed substantial improvement in categorization accuracy, with excellent discrimination between phenoconverters to PD/DLB (blue ellipse) and nonphenoconverters (red ellipse). Finally, we used this approach to classify the 3 subjects with RBD who later phenoconverted to possible or probable MSA. Although the 2-category predictive model was derived from phenoconverters to PD/ DLB and nonphenoconverters, the phenoconverters to MSA formed a discrete cluster (green ellipse) based on their low (subnormal) network activity and relatively young age at the time of imaging. A 3-category logistical model based on the data (figure 4B) had excellent goodness of fit, correctly classifying 19 of 20 (95%) of the subjects with RBD (p , 0.0001).
DISCUSSION In this study, we report elevated expression of the PDRP, an abnormal disease-related metabolic brain network, in subjects with idiopathic RBD. Indeed, significant increases in network activity were found in 2 separate RBD cohorts, at levels consistent with prodromal PD. Long-term clinical follow-up data suggested that phenoconversion was more likely in individual RBD subjects with networklevel functional abnormalities at baseline.
The current study extends the prior observations of dopaminergic deficits in RBD and the relationship of these changes to incipient PD. 22, 23 Of note, the PDRP network has several advantages compared with dopaminergic imaging techniques. While PDRP expression is associated with both presynaptic nigrostriatal dopaminergic dysfunction and Unified Parkinson's Disease Rating Scale motor ratings, 6, 24 it is worth noting that the magnitude of these correlations is modest. Indeed, individual differences in any of these descriptors account for no more than one-third of the variation in the other 2 measures. 10 It is therefore likely that the PDRP increases seen in some subjects with RBD denote a specific functional aspect of the disease prodrome that is not captured by striatal dopamine transporter binding measurements. In this vein, the PDRP changes may also distinguish future phenoconverters to PD/DLB from MSA-conditions not readily distinguished based on dopaminergic imaging measures. 25, 26 A direct comparison of dopaminergic imaging and network quantification techniques will be needed to clarify the strengths and weaknesses of the 2 scanning strategies.
It is also noteworthy that abnormal elevations in PDRP expression in subjects with RBD were observed using metabolic imaging with FDG-PET and substantiated in scans of cerebral perfusion using ECD SPECT. Indeed, we have found consistent network abnormalities in patients with PD scanned using the latter approach. 19, 20 The PDRP abnormality seen in both RBD cohorts accords well with the tight coupling that has been observed between network expression values in scans of cerebral blood flow and metabolism obtained in the same subjects. 8, 27 Nonetheless, FDG-PET and ECD SPECT data are not interchangeable and thus were analyzed separately.
In aggregate, our data comport with the view of RBD as the prodromal phase of a progressive systems-based neurodegenerative process. [1] [2] [3] 28 Further support is provided by the nodal measurements, which showed that regional abnormalities in the 2 RBD groups were most pronounced caudally in the pons, and that changes rostrally in the basal ganglia and thalamus were less consistent. Indeed, significant functional abnormalities were not evident in cortical PDRP network regions in either RBD cohort. This pattern is consistent with an ascending disease process. 29 Of note, we have previously reported significant metabolic abnormalities in the dorsal pons at the earliest clinical stages of PD, which increased rapidly with disease progression. 10 The underlying causes for the pontine abnormality of RBD are unknown. That this regional change was most pronounced in the phenoconverters to PD/DLB, i.e., the subjects with RBD who later developed clinical manifestations of Lewy body pathology, suggests a direct association with the neurodegenerative process itself. Nonetheless, a small nonsignificant increase in pontine activity was also present in the nonphenoconverters (figure 3B, right), compatible with the modulatory role that has been proposed for this region in the pathophysiology of RBD. 28 While PDRP expression and subject age each provided critical information regarding the likelihood of subsequent phenoconversion, final clinical status was predicted more accurately by the 2 measures in concert. In this context, subject age proved useful as an adjunct to network activity in predicting individual case outcomes. This point is illustrated by the 3 nonphenoconverters with relatively increased PDRP expression ( figure 4A, arrows) . Given that these values did not differ from those of the subjects with RBD who later phenoconverted to PD/DLB, these data represent false-negative misclassifications based on the network measurements alone. We note, however, that these individuals were correctly classified once age was taken into account. Thus, despite relatively high baseline network expression levels, these subjects were likely too young for phenoconversion to have occurred during the ensuing 5 years of clinical follow-up. In fact, based on the 2-category logistical model, these individuals were unlikely to exhibit a manifest neurodegenerative phenotype for another 2 to 3 years (i.e., 4-5 years after baseline imaging; figure 4B, arrows).
Two further points are germane to network-based predictions in subjects with idiopathic RBD. First, PDRP expression was similar for RBD phenoconverters to PD and DLB (1.42 6 0.28 [mean 6 SE] and 1.79 6 0.42, respectively). This observation is compatible with the substantial histopathologic and neurochemical overlap that has been observed between patients with PD, with or without dementia, and DLB. 30, 31 Given preliminary data suggesting comparable PDRP abnormalities in patients with PD and DLB (L. Teune, personal communication), it is perhaps not surprising that the phenoconverters to PD and DLB constituted a homogeneous group regarding this particular network. Second, the 2-variable logistical model correctly classified the 3 subjects with RBD who subsequently phenoconverted to possible/ probable MSA. This accords with the low PDRP expression values seen in patients with MSA. 32 Indeed, the 3 atypical phenoconverters exhibited negative subject scores, denoting subnormal network activity, which discriminated them from the other subjects with RBD. Moreover, in agreement with the earlier onset of MSA relative to PD/DLB, 33 these individuals proved to be younger than phenoconverters to PD or DLB (baseline age 5 58.8 6 8.3 years vs 71.4 6 4.3 years). This factor, in addition to low network activity, explains the discrete clustering of the data from these subjects with RBD. Needless to say, rigorous validation studies will be needed before this or other predictive algorithms can be used reliably to predict clinical outcome in individuals with isolated RBD.
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